Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
NCT ID: NCT07157631
Last Updated: 2025-12-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
1546 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-11-01
Study Completion Date
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We propose a multi-center randomized trial to test the primary hypothesis that tranexamic acid is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial 24 hours and that tranexamic acid is non-inferior to placebo for a composite of thrombotic events within the initial 7 postoperative days. Secondarily, we will determine whether tranexamic acid is superior to placebo on total postoperative drainage volume and blood product transfusion within the initial 3 postoperative days.
We propose to randomize patients to 2.0 g of tranexamic acid intravenously at the start of surgery or a comparable volume of 0.9% normal saline placebo. Because demonstrating safety will require more patients, our sample size is based on safety. Randomizing 1546 patients will provide 80% power for detecting a non-inferiority margin of 4% with a baseline incidence of 10% for composite thrombotic events within the initial 7 postoperative days.
We propose to randomize patients to 2.0 g of tranexamic acid intravenously at the start of surgery or a comparable volume of 0.9% normal saline placebo. Because demonstrating safety will require more patients, our sample size is based on safety. Randomizing 1546 patients will provide 80% power for detecting a non-inferiority margin of 4% with a baseline incidence of 10% for composite thrombotic events within the initial 7 postoperative days.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Tranexamic Acid or Placebo on Perioperative Bleeding in Adults Undergoing Liver Transplantation.
NCT04753151
Hemorrhage
UNKNOWN
NA
Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy
NCT00657384
Blood Loss, Surgical
TERMINATED
PHASE3
Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding
NCT03023189
Upper Digestive Bleeding
Cirrhosis
UNKNOWN
PHASE4
Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection
NCT01651182
Cancer
Tumour
Surgery
COMPLETED
PHASE3
Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
NCT00827931
Biliary Tract Surgical Procedures
Pancreaticoduodenectomy
Esophagectomy
+2 more
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
BACKGROUND Chronic liver disease and cirrhosis account for around 2 million deaths per year worldwide. Liver transplantation has evolved remarkably over the years to become the standard-of-care for end-stage liver disease\[1\]. Due to the end stage of liver disease, accompanied by metabolic and coagulation dysfunction, coupled with the complex surgical procedures and prolonged duration, the recipients are prone to massive bleeding during perioperative period. Historical records indicate that the first 100 liver transplants were associated with high mortality, with most patients succumbing to uncontrolled bleeding\[2\]. According to reports, massive intraoperative bleeding has been reported in 10%-34% of OLT cases\[3, 4\]. In a USA multi-center large-scale cohort study, the incidence rate of intraoperative packed RBCs transfusion was 81% and 12% patients received ≥10 RBC units\[5\]. With refined surgical techniques and perioperative care, perioperative bleeding for liver-transplant recipients has gradually decreased to the point where many transplant recipients require no transfusions\[6-8\]. Nonetheless, perioperative bleeding remains an important complication in many liver transplantat patients.
Tranexamic acid (TXA) is a synthetic analog of lysine that inhibits fibrinolysis by preventing plasminogen from binding to fibrin\[9\]. In the past decades, it has attracted international attention due to the extensive reduction of blood loss in a wide range of surgical procedures and improves survival rates in patients with severe bleeding\[10, 11\]. It is particularly recommended for surgeries with an anticipated blood loss exceeding 500 mL\[12\]. In a series of international large-scale trials studied in patients having cardiac surgery, trauma, cesarean sections, and non-cardiac surgeries, use of tranexamic acid significantly reduces the incidence and severity of perioperative bleeding, decreases the need for blood transfusions, and does not lead to significant thrombotic complications or seizures\[13, 14\]. However, administration of high-dose TXA can provoke seizures and thromboembolism that may increase the risk of perioperative disability or mortality\[12\]. What's more, after many years of experience with TXA in various fields, clinicians are now querying whether the dose, route and interval of administration currently used and the methods used to control and analyze the antifibrinolytic mechanism of TXA are optimal\[15\]. These issues need to be evaluated and reviewed using the latest evidence to improve the safety and effectiveness of TXA in treating hemorrhage or bleeding in surgeries.
Postoperative bleeding is a severe threat to patients having liver transplantation because, with rare exceptions (e.g., cancer surgery), they have decompensated liver function and systemic hyper fibrinolysis. However, evidence for the perioperative use of tranexamic acid in this population remains limited and controversial \[16, 17\]. In a RCT study of 45 liver transplant patients published in the journal of Anesthesiology in 1996, TXA significantly reduced intraoperative blood loss without hepatic artery or portal vein thrombosis within 30 days of transplantation\[17\]. And in a trial of 600 advanced liver cirrhosis patients presenting with upper gastrointestinal bleeding, TXA was proven helpful in decreasing bleeding by day 5 and rebleeding by 6 weeks\[18\]. However, a retrospective cohort study of 779 liver transplantation patients and a RCT study of 1245 cancer-related resection patients concluded that intraoperative TXA administration does not lower blood loss or reduce utilization of red blood cell transfusion\[19, 20\].
A lager sample study\[20\] did not prove that tranexamic acid was effective in reducing intraoperative blood transfusion, it also did not increase postoperative thrombotic events related to large vessels and local hepatic vessels either. It is important to consider that the severity of liver disease, surgical trauma, and blood loss in the liver resection patients included in that study were much better than those with end-stage liver disease requiring OLT. Furthermore, patients scheduled for liver transplantation often present thrombocytopenia and/or a deficiency of coagulation factors produced in the liver, as well as the hyperfibrinolysis during the anhepatic and reperfusion phases, these unique pathophysiological characters make the bleeding and hemostasis strategy in OLT surgery differ from that in hepatectomy. For patients with end-stage liver disease, whether intraoperative tranexamic acid reduces blood loss and whether it increases thrombotic events is remains unclear. Despite the lack of clear evidence for increased risk of hypercoagulability consequent to use of antifibrinolytics during liver transplant, postoperative hypercoagulability and thrombotic complications remain common in clinical and provoke adverse outcomes.
Whether TXA promotes hypercoagulation and thrombotic events in OLT patients remains unknown. The delicate balance between bleeding and thrombosis after TXA administration therefore requires additional exploration. A robust trial to assess the effectiveness and safety of TXA in liver transplantation is thus needed. We therefore propose to test the primary efficacy hypothesis that TXA is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial postoperative day, and the primary safety hypothesis that TXA is non-inferior to placebo on a composite of thrombotic events within the initial 7 postoperative days. Secondarily, we propose that TXA is superior to placebo for the total amount of postoperative drainage volume and blood product transfusion within the initial 3 days after liver transplantation.
METHODS Trial design and ethics Our multi-center randomized trial will enroll 1546 patients scheduled for allogeneic liver transplantation. The trial will be performed in 24 centers. Participating patients will be randomized to TXA or placebo. The trial will be approved by the ethics committee of Renji Hospital of the Shanghai Jiao Tong University School of Medicine and by each participating hospital. The trial will be registered at ClinicalTrial.gov before the first patient is enrolled. Written informed consent will be obtained from all patients or their authorized representatives. We expect enrollment to take about 2 years.
Preparation, Anesthesia, surgery, intervention and Perioperative Management Organ donation or transplantation in the study will be implemented under regulation of Local Organ Transplant Committee and the Declaration of Helsinki. Liver grafts will be from brain dead donors or living donors. Brain dead grafts will be preserved in conventional static cold preservation for transport to transplant centers while liver donor grafts will be was injected with 0-4℃ lactated Ringer's solution and UW solution through the portal vein immediately after resection . All the surgical procedures will be performed by specialists with experience in OLTs.
Qualifying and consented patients will receive routine surgical, anesthesia and perioperative care per local practice. General anesthesia will be induced and maintained with propofol, sufentanil/remifentanil, rocuronium/cisatracurium and inhaled anesthetics. Intraoperative monitoring will include electrocardiogram, pulse oxygen saturation, intra-arterial blood pressure, airway pressure, end-tidal concentration of carbon dioxide, central venous pressure, nasopharyngeal temperature, and urine output. Thermodilution cardiac output monitoring (measured via a pulmonary artery catheter or PICCO system) or perioperative transesophageal echocardiography, bispectral index may be used when necessary. Intraoperative fluid will be given per the attending anesthesiologist's routine practice. Blood transfusion will be based on clinical need, but generally initiated when intraoperative hemoglobin is less than 70 g/L\[40\]. Plasma, platelets, and anti-fibrinolytics will be used to manage coagulopathic states per routine.
Randomization and blinding Randomization will occur shortly before surgery after consenting patients are deemed eligible and use random-sized blocks stratified by trial site and MELD scores ≥16 points. Patients will be randomized in a 1:1 ratio to receive either TXA or matching placebo. Allocations will be generated by REDCap which can be operated via computer or smartphone. The unblinded investigator will enter the eligible patient's data into the randomization application on their computer or smartphone. Once the data is submitted, the patient's treatment allocation will be immediately acquired. The trial will use a double-blind design, with the surgical team, anesthesiologists, postoperative interviewers and patients blinded to the group assignment. The unblinded investigator will prepare the drugs, ensuring the trial drug's outer packaging, color, and texture are completely identical. In patients assigned to tranexamic acid, 2.0 g dissolved in 50 ml of 0.9% saline）will be given intravenously within 30 mins after skin incision. In patients assigned to placebo, a comparable volume of 0.9% saline will be given.
Data collection Preoperative laboratory data (most recent within 3 days of surgery) will be recorded. Baseline data will include: 1) Demographic characteristics: sex, date of birth, height, weight, and body mass index (BMI); 2) Medical data: diagnosis (reason for LT), comorbidities, concomitant medication, non-drug therapies, history of smoking and drinking, history of food or drug allergy, and history of anesthesia and surgery; 3) Medical examinations including arrythmia detected by electrocardiography, heart conditions examined by echocardiography and liver diseases detected by ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI); 4) The most recent laboratory investigations that reflects liver, kidney, heart, coagulation function, complete blood count, arterial blood gas (ABG) analysis including albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine, blood urea nitrogen (BUN), troponin, international normalized ratio (INR), hemoglobin, white blood cell, pH, partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2); 5) Donor characteristics: age, height, weight, BMI, cause of death, and virology or hepatic fat deposition status. All these test results including diagnostic results of CTs or MRIs will be converted to database fields with defined values in REDCap.
Intraoperative characteristics to be recorded will include: 1). Duration of surgery, anhepatic phase, cold and warm ischemia times; 2). Fluids given (including intravenous fluids, colloids, blood products) and output (including blood loss, urine). Intraoperative bleeding (estimated by weighing surgical sponges and suction canisters before and after use), type and volume of blood products transfused, and type and volume of fluid infusion; 3). Central venous pressure, hemoglobin, arterial blood gas, electrolytes, lactic acid, and blood glucose.
Tranexamic acid (TXA) is a synthetic analog of lysine that inhibits fibrinolysis by preventing plasminogen from binding to fibrin\[9\]. In the past decades, it has attracted international attention due to the extensive reduction of blood loss in a wide range of surgical procedures and improves survival rates in patients with severe bleeding\[10, 11\]. It is particularly recommended for surgeries with an anticipated blood loss exceeding 500 mL\[12\]. In a series of international large-scale trials studied in patients having cardiac surgery, trauma, cesarean sections, and non-cardiac surgeries, use of tranexamic acid significantly reduces the incidence and severity of perioperative bleeding, decreases the need for blood transfusions, and does not lead to significant thrombotic complications or seizures\[13, 14\]. However, administration of high-dose TXA can provoke seizures and thromboembolism that may increase the risk of perioperative disability or mortality\[12\]. What's more, after many years of experience with TXA in various fields, clinicians are now querying whether the dose, route and interval of administration currently used and the methods used to control and analyze the antifibrinolytic mechanism of TXA are optimal\[15\]. These issues need to be evaluated and reviewed using the latest evidence to improve the safety and effectiveness of TXA in treating hemorrhage or bleeding in surgeries.
Postoperative bleeding is a severe threat to patients having liver transplantation because, with rare exceptions (e.g., cancer surgery), they have decompensated liver function and systemic hyper fibrinolysis. However, evidence for the perioperative use of tranexamic acid in this population remains limited and controversial \[16, 17\]. In a RCT study of 45 liver transplant patients published in the journal of Anesthesiology in 1996, TXA significantly reduced intraoperative blood loss without hepatic artery or portal vein thrombosis within 30 days of transplantation\[17\]. And in a trial of 600 advanced liver cirrhosis patients presenting with upper gastrointestinal bleeding, TXA was proven helpful in decreasing bleeding by day 5 and rebleeding by 6 weeks\[18\]. However, a retrospective cohort study of 779 liver transplantation patients and a RCT study of 1245 cancer-related resection patients concluded that intraoperative TXA administration does not lower blood loss or reduce utilization of red blood cell transfusion\[19, 20\].
A lager sample study\[20\] did not prove that tranexamic acid was effective in reducing intraoperative blood transfusion, it also did not increase postoperative thrombotic events related to large vessels and local hepatic vessels either. It is important to consider that the severity of liver disease, surgical trauma, and blood loss in the liver resection patients included in that study were much better than those with end-stage liver disease requiring OLT. Furthermore, patients scheduled for liver transplantation often present thrombocytopenia and/or a deficiency of coagulation factors produced in the liver, as well as the hyperfibrinolysis during the anhepatic and reperfusion phases, these unique pathophysiological characters make the bleeding and hemostasis strategy in OLT surgery differ from that in hepatectomy. For patients with end-stage liver disease, whether intraoperative tranexamic acid reduces blood loss and whether it increases thrombotic events is remains unclear. Despite the lack of clear evidence for increased risk of hypercoagulability consequent to use of antifibrinolytics during liver transplant, postoperative hypercoagulability and thrombotic complications remain common in clinical and provoke adverse outcomes.
Whether TXA promotes hypercoagulation and thrombotic events in OLT patients remains unknown. The delicate balance between bleeding and thrombosis after TXA administration therefore requires additional exploration. A robust trial to assess the effectiveness and safety of TXA in liver transplantation is thus needed. We therefore propose to test the primary efficacy hypothesis that TXA is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial postoperative day, and the primary safety hypothesis that TXA is non-inferior to placebo on a composite of thrombotic events within the initial 7 postoperative days. Secondarily, we propose that TXA is superior to placebo for the total amount of postoperative drainage volume and blood product transfusion within the initial 3 days after liver transplantation.
METHODS Trial design and ethics Our multi-center randomized trial will enroll 1546 patients scheduled for allogeneic liver transplantation. The trial will be performed in 24 centers. Participating patients will be randomized to TXA or placebo. The trial will be approved by the ethics committee of Renji Hospital of the Shanghai Jiao Tong University School of Medicine and by each participating hospital. The trial will be registered at ClinicalTrial.gov before the first patient is enrolled. Written informed consent will be obtained from all patients or their authorized representatives. We expect enrollment to take about 2 years.
Preparation, Anesthesia, surgery, intervention and Perioperative Management Organ donation or transplantation in the study will be implemented under regulation of Local Organ Transplant Committee and the Declaration of Helsinki. Liver grafts will be from brain dead donors or living donors. Brain dead grafts will be preserved in conventional static cold preservation for transport to transplant centers while liver donor grafts will be was injected with 0-4℃ lactated Ringer's solution and UW solution through the portal vein immediately after resection . All the surgical procedures will be performed by specialists with experience in OLTs.
Qualifying and consented patients will receive routine surgical, anesthesia and perioperative care per local practice. General anesthesia will be induced and maintained with propofol, sufentanil/remifentanil, rocuronium/cisatracurium and inhaled anesthetics. Intraoperative monitoring will include electrocardiogram, pulse oxygen saturation, intra-arterial blood pressure, airway pressure, end-tidal concentration of carbon dioxide, central venous pressure, nasopharyngeal temperature, and urine output. Thermodilution cardiac output monitoring (measured via a pulmonary artery catheter or PICCO system) or perioperative transesophageal echocardiography, bispectral index may be used when necessary. Intraoperative fluid will be given per the attending anesthesiologist's routine practice. Blood transfusion will be based on clinical need, but generally initiated when intraoperative hemoglobin is less than 70 g/L\[40\]. Plasma, platelets, and anti-fibrinolytics will be used to manage coagulopathic states per routine.
Randomization and blinding Randomization will occur shortly before surgery after consenting patients are deemed eligible and use random-sized blocks stratified by trial site and MELD scores ≥16 points. Patients will be randomized in a 1:1 ratio to receive either TXA or matching placebo. Allocations will be generated by REDCap which can be operated via computer or smartphone. The unblinded investigator will enter the eligible patient's data into the randomization application on their computer or smartphone. Once the data is submitted, the patient's treatment allocation will be immediately acquired. The trial will use a double-blind design, with the surgical team, anesthesiologists, postoperative interviewers and patients blinded to the group assignment. The unblinded investigator will prepare the drugs, ensuring the trial drug's outer packaging, color, and texture are completely identical. In patients assigned to tranexamic acid, 2.0 g dissolved in 50 ml of 0.9% saline）will be given intravenously within 30 mins after skin incision. In patients assigned to placebo, a comparable volume of 0.9% saline will be given.
Data collection Preoperative laboratory data (most recent within 3 days of surgery) will be recorded. Baseline data will include: 1) Demographic characteristics: sex, date of birth, height, weight, and body mass index (BMI); 2) Medical data: diagnosis (reason for LT), comorbidities, concomitant medication, non-drug therapies, history of smoking and drinking, history of food or drug allergy, and history of anesthesia and surgery; 3) Medical examinations including arrythmia detected by electrocardiography, heart conditions examined by echocardiography and liver diseases detected by ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI); 4) The most recent laboratory investigations that reflects liver, kidney, heart, coagulation function, complete blood count, arterial blood gas (ABG) analysis including albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine, blood urea nitrogen (BUN), troponin, international normalized ratio (INR), hemoglobin, white blood cell, pH, partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2); 5) Donor characteristics: age, height, weight, BMI, cause of death, and virology or hepatic fat deposition status. All these test results including diagnostic results of CTs or MRIs will be converted to database fields with defined values in REDCap.
Intraoperative characteristics to be recorded will include: 1). Duration of surgery, anhepatic phase, cold and warm ischemia times; 2). Fluids given (including intravenous fluids, colloids, blood products) and output (including blood loss, urine). Intraoperative bleeding (estimated by weighing surgical sponges and suction canisters before and after use), type and volume of blood products transfused, and type and volume of fluid infusion; 3). Central venous pressure, hemoglobin, arterial blood gas, electrolytes, lactic acid, and blood glucose.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Liver Transplantation
Tranexamic Acid
End-stage Liver Disease (ESLD)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
tranexamic acid group
In patients assigned to tranexamic acid, 2.0 g dissolved in 50 ml of 0.9% saline）will be given intravenously within 30 mins after skin incision.
Group Type
EXPERIMENTAL
tranexamic acid
Intervention Type
DRUG
In patients assigned to tranexamic acid, 2.0 g dissolved in 50 ml of 0.9% saline）will be given intravenously within 30 mins after skin incision.
control group
In patients assigned to placebo, a comparable volume of 0.9% saline will be given.
Group Type
PLACEBO_COMPARATOR
0.9 % saline
Intervention Type
DRUG
In patients assigned to placebo, a comparable volume of 0.9% saline will be given.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tranexamic acid
In patients assigned to tranexamic acid, 2.0 g dissolved in 50 ml of 0.9% saline）will be given intravenously within 30 mins after skin incision.
Intervention Type
DRUG
0.9 % saline
In patients assigned to placebo, a comparable volume of 0.9% saline will be given.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\-
Exclusion Criteria
\-
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
Sponsor Role
lead
West China Hospital
OTHER
Sponsor Role
collaborator
The Affiliated Hospital of Qingdao University
OTHER
Sponsor Role
collaborator
The First Affiliated Hospital of Zhengzhou University
OTHER
Sponsor Role
collaborator
Huashan Hospital
OTHER
Sponsor Role
collaborator
Tianjin First Central Hospital
OTHER
Sponsor Role
collaborator
The First Hospital of Jilin University
OTHER
Sponsor Role
collaborator
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
Sponsor Role
collaborator
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Sponsor Role
collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
Sponsor Role
collaborator
The First Affiliated Hospital with Nanjing Medical University
OTHER
Sponsor Role
collaborator
Tongji Hospital
OTHER
Sponsor Role
collaborator
People's Hospital of Guangxi Zhuang Autonomous Region
OTHER
Sponsor Role
collaborator
The First Affiliated Hospital of University of Science and Technology of China
OTHER
Sponsor Role
collaborator
The First Affiliated Hospital of Anhui Medical University
OTHER
Sponsor Role
collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Sponsor Role
collaborator
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Sponsor Role
collaborator
Fujian Medical University Union Hospital
OTHER
Sponsor Role
collaborator
First Affiliated Hospital of Guangxi Medical University
OTHER
Sponsor Role
collaborator
Second Affiliated Hospital of Guangzhou Medical University
OTHER
Sponsor Role
collaborator
Zhejiang University
OTHER
Sponsor Role
collaborator
Hebei Medical University Third Hospital
OTHER
Sponsor Role
collaborator
Shandong First Medical University
OTHER
Sponsor Role
collaborator
Jinling Hospital, Medical School of Nanjing University
UNKNOWN
Sponsor Role
collaborator
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
liqun yang, MD, phD
Role: PRINCIPAL_INVESTIGATOR
Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
weifeng yu, MD, phD
Role: PRINCIPAL_INVESTIGATOR
Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anesthesiology, Renji Hospital, Shanghai Jiao Tong university school of medicine.
Shanghai, Shanghai Municipality, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LY2025-220-C
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Plasma Transfusion in Liver Transplantation
NCT00235183
COMPLETED
PHASE4
Tranexamic Acid for Acute Upper Gastrointestinal Bleed in Cirrhosis
NCT04489108
UNKNOWN
NA
Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation
NCT01563458
COMPLETED
PHASE2
Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation
NCT01481974
COMPLETED
PHASE1
Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy.
NCT04367155
UNKNOWN
NA
Use of Tranexamic Acid in the Total Knee Arthroplasty.
NCT05919615
COMPLETED
NA
Efficacy Comparison of Topical and Intravenous Tranexamic Acid to Reduce the Number of Blood Transfusions in TKA
NCT01881568
COMPLETED
PHASE3
The Effect of ACT and Tranexamic Acid on Bleeding in Cardiac Surgery
NCT06109155
RECRUITING
PHASE4
The Efficacy and Safety of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty
NCT02504125
COMPLETED
PHASE4
Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias
NCT07125508
COMPLETED
PHASE2/PHASE3
.Patient Blood Management Program in Liver Transplantation
NCT05187637
UNKNOWN
Viscoelastic Tests-Guided Therapy In Liver Transplantation
NCT03756948
COMPLETED
NA
Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery
NCT06414031
RECRUITING
PHASE3
Evaluation of the Safety and Efficacy of the Second Dose of Tranexamic Acid
NCT03846973
COMPLETED
PHASE3
The Efficacy of the Administration of Fibrinogen in Liver Transplantation
NCT01539057
UNKNOWN
PHASE3
Fibrinogen in Liver Transplant
NCT07265843
NOT_YET_RECRUITING
PHASE4
Tranexamic Acid and Blood Clots in Knee Surgery
NCT02867163
COMPLETED
Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy
NCT02253810
COMPLETED
NA
Impact of Tranexamic Acid Use in Percutaneous Nephrolithotomy
NCT02966236
UNKNOWN
PHASE4
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in ABO-Incompatible Liver Transplantation
NCT05666453
TERMINATED
PHASE2
Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure
NCT04410042
TERMINATED
PHASE3
Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid
NCT01643135
COMPLETED
PHASE4
Fibrinogen in Liver Transplant Subjects
NCT06764927
NOT_YET_RECRUITING
PHASE4
Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation
NCT06710327
NOT_YET_RECRUITING
PHASE4
Tranexamic Acid for The Treatment of Gastrointestinal Bleeding
NCT03540368
SUSPENDED
NA